Abzena Launches LabZient™, an Analytical platform to Expedite the Path to IND for Antibodies
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.